Endocrine therapy for gynecological cancer

Gynecological Endocrinology

Volumn 13, Issue 6, 1999, Pages 441-456

  Gadducci, A ^b   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Breast cancer; Endocrine therapy; Endometrial cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CORTICOSTEROID; EXEMESTANE; FORMESTANE; GESTAGEN; GESTONORONE; GONADORELIN AGONIST; HYDROXYPROGESTERONE CAPROATE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROGESTERONE DERIVATIVE; TAMOXIFEN; TOREMIFENE; VOROZOLE;

ATAXIA; BREAST CANCER; CANCER HORMONE THERAPY; CONFUSION; DROWSINESS; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LIVER DISEASE; MUSCLE CRAMP; OBESITY; OVARY CANCER; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; VAGINA BLEEDING;

EID: 0033374818     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599909167590     Document Type: Review

References (128)

1. 1. Howell A. Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. Proc R Soc Edin 1989;95B:49-57
2. 2. Gadducci A, Genazzani AR. Steroid hormones in endometrial and breast cancer. Eur J Gynaecol Oncol 1997;18:371-8
3. 3. Sauten RJ. Novel methods of oestrogen deprivation for treatment of breast diseases. Proc R Soc Edin 1989;95B:255-69
4. 4. Simpson ER, Mendelson CR. The regulation of oestrogen biosynthesis in human adipose tissues. Proc R Soc Edin 1989;95B:153-9
5. 5. Milewich L, Porter JC. In situ steroid sulphatase activity in human epithelial carcinoma cells of vaginal, ovarian, and endometrial origin. J Clin Endocrinol Metab 1987;65:164-9
6. 6. Yamaki J, Yamamoto T, Okada H. Aromatization of androstenedione by normal and neoplastic endometrium of the uterus. J Steroid Biochem 1985;22:63-6
7. 7. Sevelda P, Denison U, Schemper M, et al. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol 1990;97:706-12
8. 8. Kommoss F, Pfisterer J, Thome M, et al. Steroid receptors in ovarian carcinoma: immunohistochcmical determination may lead to new aspects. Gynecol Oncol 1992;47:317-22
9. 9. Parmar H, Rustin G, Lightman SL, et al. Response to D-Trp-6-luteinizing hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J 1988;296:1229
10. 10. Kullander S. LHRH agonist treatment in ovarian cancer. In Conte PF, Ragni N, Rosso R, et al., eds. Multimodal Treatment of Ovarian Cancer. New York: Raven Press, 1989:307-11
11. 11. Emons G, Ortmann O, Pahwa GS, et al. LH-RH agonists in the treatment of ovarian cancer. In Hoftken K, ed. Peptides in Oncology I. LH-RH Agonists and Antagonists. Berlin: Springer-Verlag, 1992:55-68
12. 12. Jager W, Wild L, Lang N. Some observations on effects of a Gn-RH analog in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1989;32:137-48
13. 13. Carnino F, Iskra L, Fuda G, et al. The treatment of progressive ovarian carcinoma with D-Trp-LH-RH (Decapeptyl). Eur J Cancer 1994;30A: 1903-4
14. 14. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984;36:245-76
15. 15. Camaggi CM, Strocchi E, Pannuti F. Tamoxifen pharmacokinetics in advanced breast cancer patients. In Pannuti F, ed. Anti-oestrogens in Oncology. Past, Present and Prospects. Amsterdam: Elsevier Science, 1985:90-7
16. 16. Gorodesky GI, Beery R, Lunenfeld B, et al. Tamoxifen increases plasma estrogcn-binding equivalents and has an estradiol agonistic effect on histologically normal pre-menopausal and postmenopausal endometrium, Fertil Steril 1992;57: 300-27
17. 17. Cohen I, Beyth Y, Altaras MM, et al. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Gynecol Oncol 1997;67:8-15
18. 18. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy, Clin Cancer Res 1995;1:467-72
19. 19. Pearl ML, Suzuki N, Terashima I, et al. DNA adducts detected in endometrial tissue of women treated with tamoxifen [abstr 1386]. Proc Am Soc Clin Oncol 1999;18:359
20. 20. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6
21. 21. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33
22. 22. Cushman M, Costantino JP, Bovill EG, et al. Effect of tamoxifen on cardiac risk factors in women without cancer: The Breast Cancer Prevention Trial [abstr 283]. Proc Am Soc Clin Oncol 1999;18:75
23. 23. Hard GC, Iatropoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993;53:4534-41
24. 24. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 1998;16:348-53
25. 25. Tomas E, Kauppila A, Blanco G, et al. Comparison between the effects of tamoxifen and toremifcne on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995;59: 261-6
26. 26. Alexieva-FiguschJ, Blanckestein MA, Hop WCJ, et al. Treatment of metastatic breast cancer patients with different doses of megestrol acetate: dose-relations, metabolic and endocrine effects. Eur J Cancer Clin Oncol 1984;20:33-44
27. 27. Allegra JC, Kiefer SM. Mechanism of action of progestational agents. Semin Oncol 1985;12:3-5
28. 28. Pannuti F, Camaggi CM, Strocchi E, et al. Medroxyprogesterone acetate pharmacokinetics. In Pellegrini A, Robustelli della Cuna G, Pannuti F, et al., eds. Role of Medroxyprogesterone in Endocrine-related Tumors, vol. 3. New York: Raven Press, 1984:43-77
29. 29. Camaggi CM, Strocchi E, Pannuti F. Medrossiprogesterone acetato: farmacocinetica e farmacodinamica. Progr Oncol Clin 1988;1:21-9
30. 30. Willemse PHB, Bonomi P, Gale M, et al. Adrenal steroids as parameters of the bioavailability of megestrol acetate and medroxyprogesterone acetate. Eur J Cancer 1990;26A:359-62
31. 31. Brodie AMH, Santen RJ. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. CRC Crit Rev Oncol Hematol 1986;5:361-96
32. 32. Lonning PE, Johannessen DC, Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989;60:107-11
33. 33. Santen RJ. The principles of aromatase inhibition in the treatment of breast cancer. In Jonat W, Santen RJ, eds. Aromatase Inhibition. Present and Future. Carnforth, UK: Parthenon Publishing, 1991:11-27
34. 34. Dowsett M. Pharmacodynamic and endocrine effects of 4-hydroxyandrostenedione in patients with breast cancer. Adv Clin Oncol 1994;2:131-4
35. 35. Brodie AHM, Schwarzel WC, Shikh AA, et al. The effect of an aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione on estrogen dependent processes in reproduction and breast cancer. Endocrinology 1977;100:1684-95
36. 36. Dowsett M, Cunningham DC, Stein RC. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandro-stenedione in postmenopausal breast cancer patients. Cancer Res 1989;49:1306-12
37. 37. Dowsett M. Endocrine aspects of 4-hydroxy-androstenedione, a new aromatase inhibitor. In Jonat W, Santen RJ, eds. Aromatase Inhibition. Present and Future. Carnforth, UK: Parthenon Publishing, 1991:47-56
38. 38. Di Salle E, Evans TRJ, Ornati G, et al. Exemestane, a novel steroidal aromatase inhibitor. Adv Clin Oncol 1994;2:165-71
39. 39. Kaufmann M, Bajetta E, Dirix LY, et al. Survival advantage of exemestane (EXE, Aromasin) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study [abstr 412]. Proc Am Soc Clin Oncol 1999;18:109
40. 40. Buzdar A, Jonat W, Howell A, et al., for the Arimidex International Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11
41. 41. Jonat W, Howell A, Blomqvist C, et al., on behalf of the Arimidex International Study Group. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12
42. 42. Dombemowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61
43. 43. Gershanovich M, Chaudri HA, Campos D, et al., for the Letrozole International Group (AR/BC3). Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9:639-45
44. 44. Goss P, Wiener E, Tannock I, et al., for the North American Vorozole Study Group. Vorozole vs Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifcn [abstr]. J Clin Oncol 1997;16:155
45. 45. Geisler J, Bernsten H, Ottestad L, et al. Neoadjuvant treatment with anastrozole ('Arimidex') causes profound suppression of intra-tumor estrogen levels [abstr 311]. Proc Am Soc Clin Oncol 1999;18:82
46. 46. Van den Bossche H, Willemsens G, Rods I, et al. R 76713 and enantiomers: selective, non steroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. Biochem Pharmacol 1990;40:1707-18
47. 47. De Coster R, Wouters W, van Ginkel R, et al. Pharmacology of vorozole, a new potent and selective non-steroidal aromatase inhibitor. Adv Clin Oncol 1994;2:173-7
48. 48. Klingmuller D, Schweikert HU. Gonadotropinreleasing hormone: physiological and endocrinological aspects. In Hoffken K, ed. Peptides in Oncology I. LH-RH Agonists and Antagonists. Berlin: Springer-Verlag, 1992:1-6
49. 49. Manni A. GnRH agonist in premenopausal breast cancer. In Filicori M, Flamigni C, Treatment with GnRH Analogs: Controversies and Perspectives. Carnforth, UK: Parthenon Publishing, 1996:145-9
50. 50. Baumann KH, Kiesel L, Kaufmann M, et al. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993;25: 37-46
51. 51. Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990;50: 1841-6
52. 52. Skralovic G, Schally AV, Wittliff JL, et al. Presence and characteristics of receptors for [D-Trp6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489-98
53. 53. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84
54. 54. Taylor CW, Green S, Dalton WS, et al. Multi-center randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998;16:994-9
55. 55. Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997; 44:201-10
56. 56. Saphner T, Troxel AB, Tormey DC, et al. Phase II study of goserelin for patients with premenopausal metastatic breast cancer. J Clin Oncol 1993;11:1529-35
57. 57. Bajetta E, Celio L, Zilembo N, et al. Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer. Tumori 1994;80:28-32
58. 58. Walker KJ, Walker RF, Turkes A, et al. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol 1989;25:651-4
59. 59. Jonat W, Kaufmann M, Blamey RW, et al. A randomised study to compare the effect of luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre-and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995;31A:137-42
60. 60. Boccardo F, Blarney RW, Klijn JGM, et al. LHRH-agonist (LHRH-A) + tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): results of a meta-analysis of four trials [abstr 416]. Proc Am Soc Clin Oncol 1999;18:110
61. 61. Jackson IM, Lowery C. Clinical uses of anti-oestrogens. In Furr BJA, Wakeling AE, eds. Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action. London: Baillière Tindall, 1987:87-105
62. 62. Mouridsen HT. Future developments in the endocrine treatment of advanced breast cancer. In Jonat W, Santen RJ, eds. Aronatase Inhibition. Present and Future. Carnforth, UK: Parthenon Publishing, 1991:99-107
63. 63. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556-66
64. 64. Gams RA, Vogel CL. Toremifene (TOR): an active agent in the management of postmenopausal women with advanced breast cancer refractory to tamoxifen (TAM) [abstr 504]. Proc Am Soc Clin Oncol 1999;18:132
65. 65. Pannuti F, Martoni A, Lenaz GR, et al. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 1978;62: 499-504
66. 66. Robustelli della Cuna G, Calciati A, Strada MR, et al. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.Tumori 1978; 64:143-9
67. 67. Cavalli F, Goldhirsch A, Jung F, et al. Randomised trial of low-vs high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer: The Swiss Group for Clinical Cancer Research. J Clin Oncol 1984;2:414-19
68. 68. Robustelli della Cuna G, Pavesi G, Preti L, et al. Il megestrolo acetato nel trattamento del carcinoma mammario in fase avanzata. Prog Oncol Clin 1991;2:47-63
69. 69. Muss HB, Case LD, Capizzi RL, et al. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990;8:1797-805
70. 70. Tchekmedyian NS, Tait N, Abrams J, et al. High-dose megestrol acetate in the treatment of advanced breast cancer. Semin Oncol 1988;15 (suppl 1):44-9
71. 71. Parnes HL, Abrams JS, Tchekniedyian NS, et al. A phase I/II study of high dose mcgcstrol acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991;18:171-7
72. 72. Kaye SB, Woods RL, Fox RM, et al. Use of aminoglutethimidc as second-line endocrine therapy in metastatic breast cancer. Cancer Res 1982;42(Suppl):3445-7
73. 73. Canney PA, Priestman TJ, Griffiths TH, et al. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate for advanced breast carcinoma. J Natl Cancer Inst 1988;80:1147-51
74. 74. Cocconi G, Bisagni G, Ceci G, et al. Low dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1992; 10:984-9
75. 75. Coombes RC. 4-hydroxyandrostenedione in the treatment of advanced breast cancer. In Jonat W, Santen RJ, eds. Aromatase Inhibition. Present and Future. Carnforth, UK: Parthenon Publishing, 1991:57-62
76. 76. Hoffken K, Jonat W, Possinger K. Clinical experience with 4-hydroxyandrostenedione in the treatment of advanced breast cancer. In Jonat W, Santen RJ, eds. Aromatase Inhibition. Present and Future Carnforth, UK: Parthenon Publishing, 1991:65-76
77. 77. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999;10:377-84
78. 78. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-67
79. 79. Bonte J, Decoster JM, Ide P, et al. Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 1978;6:60-75
80. 80. Kauppila A. Progestin therapy of endometrial, breast, and ovarian carcinoma. Acta Obstet Gynecol Scand 1984;63:441-50
81. 81. Piver MS, Barlow JJ, Lurain JR, et al. Medroxyprogesterone acetate (Depo-Provera) vs hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 1980;45:268-72
82. 82. Thigpen JT, Blessing J, Di Saia P. Treatment of advanced or recurrent endometrial carcinoma with medroxyprogesterone acetate. Gynecol Oncol 1985;20:250-7
83. 83. Podratz KC, O'Brien PC, Malkasian GD Jr, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66: 106-10
84. 84. Lentz SS. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol 1994; 21:100-6
85. 85. Crespo C, Gonzalez-Martin A, Lastra E, et al. Metastatic endometrial cancer in lung and liver: complete and prolonged response to hormonal therapy with progestins. Gynecol Oncol 1999;72: 250-5
86. 86. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 1998;83: 111-21
87. 87. Saegusa M, Okayasu I. Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. J Pathol 1997;182:429-36
88. 88. Fujimoto J, Sakaguchi H, Hirose R, et al. Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells. Cancer Lett 1999;141:63-71
89. 89. Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol 1989;32:1-3
90. 90. Trope C, Kristensen G. Current status of chemotherapy in gynecologic cancer. Semin Oncol 1997; 24 (suppl 15):1-22
91. 91. Edmonson JH, Krook JE, Hilton JF, et al Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment. Cancer Treat Rep 1986;70:1019-20
92. 92. Nola M, Jukic S, Ilic-Forco J, et al. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. Gynecol Oncol 1999;72:331-6
93. 93. Zaino RJ, Satyaswaroop PG, Mortel R. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 1985;45:539-41
94. 94. Kline RC, Freedman RS, Jones LA, et al. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat Rep 1987;71:327-8
95. 95. Huffman MS, Roberts WS, Canavag D, et al. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. Gynecol Oncol 1989;35:75-7
96. 96. Pinelli DM, Fiorica JV, Roberts WS, et al. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study. Gynecol Oncol 1996;60: 462-7
97. 97. Gallagher CJ, Oliver RT, Oram DH, et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 1991;98:1037-41
98. 98. Gallagher CJ, Oram DH, Jeyarajah AR, et al. Gonadotrophin releasing hormone analogue (GnRH) treatment for recurrent progestagen resistant endometrial cancer. Br J Cancer 1996; 74:16
99. 99. Kim JW, Lee YS, Kim BK, et al. Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog. Gynecol Oncol 1999;73:368-71
100. 100. Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997;64:126-9
101. 101. De Palo G, Spatti GB, Bandieramonte G, et al. Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion. Tumori 1983;69:65-7
102. 102. Lewis GC, Nelson HS, Mortel R, et al. Adjuvant progestagen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 1974;2:368-76
103. 103. Malkasian GD Jr, Decker DG. Adjuvant progesterone therapy for stage I endometrial carcinoma. Int J Gynaecol Obstet 1978;16:48-9
104. 104. MacDonald RR, Thorogood J, Mason MK. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obslet Gynaecol 1988;95:166-74
105. 105. Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011-16
106. 106. De Palo G, Mangioni C, Periti P, et al. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 1993;29A: 1133-40
107. 107. Maggino T, Romagnolo C, Zola P, et al. An analysis of approaches to the treatment of endometrial cancer in Western Europe: a CTF study. Eur J Cancer 1995; 31A:1993-5
108. 108. Maggino T, Romagnolo C, Landoni F, et al. An analysis of approaches to the management of endometrial cancer in North America: a CTF study. Gynecol Oncol 1998;68:274-9
109. 109. Piver MS, Recio FO, Baker TR, et al. A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma. Gynecol Oncol 1992;47:373-6
110. 110. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:60-5
111. 111. Gadducci A, Sartori E, Landoni F, et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;63: 247-53
112. 112. Tsukamoto N, Kamura T, Matsukuma K, et al. Endolymphatic stromal myosis: a case with positive estrogen and progesterone receptors and good response to progestins. Gynecol Oncol 1985; 20:120-8
113. 113. Montag TW, Manart FD. Endolymphatic stromal myosis: surgical and hormonal therapy for extensive venous recurrence. Gynecol Oncol 1989; 33:255-60
114. 114. Katz L, Merino MJ, Sakamoto H, et al. Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol 1987;26:87-97
115. 115. Scribner DR Jr, Walker JL. Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Gynecol Oncol 1998;71:458-60
116. 116. Weiner SA, Alberts DS, Surwit EA, et al. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987;27:208-13
117. 117. Beechman JB, Blessing J, Creasman W, et al. Tamoxifen responsiveness, hormone receptors, and tumor grade: a prospective study of 105 advanced ovarian cancer patients [abstr]. Gynecol Oncol 1988;29:136
118. 118. Vermorken JB, De Oliveira CF, Ten Bokkel Huinink WW, et al. Chemotherapy in advanced ovarian cancer. The EORTC experience. In Conte PF, Ragni N, Rosso R, et al., eds. Multimodal Treatment of Ovarian Cancer. New York: Raven Press, 1989:255-64
119. 119. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993;11:1957-68
120. 120. Ercoli A, Scambia G, De Vincenzo R, et al. Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as possible mechanisms. Cancer Lett 1996;108:7-14
121. 121. Schwartz PE, Chambers JT, Kohorn EI, et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989;63:1074-8
122. 122. Emons G, Ortmann O, Teichert HM, et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996;78:1452-60
123. 123. Ohta H, Sakamoto H, Satoh K. In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett 1998;134:111-18
124. 124. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997;15:840-52
125. 125. Palyi I, Vincze B, Lovas S, et al. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc Natl Acad Sci USA 1999;96:2361-6
126. 126. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. J Am Med Assoc 1999; 281:2189-97
127. 127. Gadducci A, Romanini A, Cosio S, et al. Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study. Anticancer Res 1999;19:2253-6
128. 128. Van der Vange N, Greggi S, Burger CW, et al. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995;34: 813-20